scispace - formally typeset
B

Bayard D. Clarkson

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  383
Citations -  27729

Bayard D. Clarkson is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Leukemia & Bone marrow. The author has an hindex of 84, co-authored 383 publications receiving 27241 citations. Previous affiliations of Bayard D. Clarkson include University of Texas Southwestern Medical Center & Kettering University.

Papers
More filters
Journal ArticleDOI

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

TL;DR: The results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.

Structural Mechanism for STI-571 Inhibition of Abelson

TL;DR: The crystal structure of the catalytic domain of the Abelson tyrosine kinase (Abl) complexed to a variant of STI-571 is reported in this paper.
Journal ArticleDOI

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

TL;DR: The prognostic significance of disease features recorded at the time of diagnosis was examined among 813 patients with Philadelphia chromosome- positive, nonblastic chronic granulocytic leukemia (CGL) collected from six European and American series, and it should be possible to identify a lower risk group of patients with a 2-yr survival of 90%, subsequent risk averaging somewhat less than 20%/yr and median survival of 5 yr.
ComponentDOI

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

TL;DR: In this article, the authors report crystal structures of the kinase domain of Abl in complex with two small molecule inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).